演讲嘉宾简介

以下演讲人将于本届 ChinaBio^® 创业投资论坛做出精彩演讲。

主题演讲人：

William Keller - Vice GM/Chairman, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd. / HBM BioMed China

Mr. William Keller is a highly energetic and determined Senior Corporate Executive with a rich experience in pharmaceuticals in South America and Asia Pacific, with a focus on China. Mr. Keller enjoys a high reputation for strong leadership, business acumen, excellent negotiation skills and cultural sensitivity, all of which have created strong personal relationships and credibility with governments, customers, staff and press. Awarded Honorary Citizen of Shanghai by the municipal government, Mr. Keller is also holder of a permanent resident permit. Mr. Keller graduated from School of Economics and Business Administration (Zurich) in 1972 and has taken several Management and Leadership Courses at IMD and London Business School during 1990-2001.
Mr. Keller has been the General Manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2002, during which he formulated, developed overall Roche strategy for China including negotiation and establishment of 5 joint ventures and one holding company reaching sale end of 2002 of USD 300 million and staff of 1900 people and developed Roche to a leading pharmaceutical company in the China market with annual sales of USD 150 million. Managing Director (1990-2002) and Area Manager Far East for Vitamin Division (1991-1993) of Roche (Hong Kong), General Manager of Roche (Columbia) from (1988-1990) and Deputy General Manager of Roche Brazil (1976-1988). Dedicated to the development of biopharmaceutical industry in Shanghai, Mr. Keller started his own business in early 2003. Keller Pharma Consultancy (Shanghai) Company works as a bridge connecting SMEs and start-ups in Shanghai with possible partners and/or investors around the world. Besides managing his own consulting company, Mr. Keller is also Consultant to Zhangjiang Biotech & Pharmaceutical Base, Honorary President of RDPAC (R&D-based Pharmaceutical Association in China), Vice Chairman of Shanghai Association of Foreign Investment Enterprises, Board member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and TaiGen Biotechnology Co., Ltd. and Senior Consultant of Shanghai Foreign Investment Development Board. Since 2007, he is Chairman of HBM Biomed China.

Greg B. Scott - President & Founder, ChinaBio^® LLC

Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded the ChinaBio^® LLC in January 2007 to help fund and mentor early stage life science companies in China, and provide consulting and research services to pharma and biotech companies with business interests in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of ChinaBio^® Today. He is also a strategic adviser to ChinaSF, an initiative of the Mayor of San Francisco to connect China and San Francisco business interests. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.

演讲嘉宾及专题研讨成员:

Robert W. Armstrong, PhD - Vice President, Global External R&D, Eli Lilly and Company

Dr. Robert W. Armstrong became vice president of global external research and development for Eli Lilly and Company in November 2006. He previously was vice president of discovery chemistry research. Armstrong's new position will serve to accelerate LRL's ability to access external innovation, including scientific and medical capabilities and capacity, as well as new drug candidates. He is also a member of the senior management council.
Prior to joining Lilly in November 1999, Armstrong had been director and head of small molecule drug discovery at Amgen, Inc.
He received Bachelor of Science degrees in chemistry and biochemistry from the University of California at San Diego in 1979 and a doctorate degree in chemistry from Colorado State University in 1984. Upon completion of an NIH postdoctoral fellowship at Harvard University in 1986, was a faculty member in the Department of Chemistry and Biochemistry at the University of California at Los Angeles, where he remains an adjunct faculty member.

Adam Kearney, JD - Of Counsel, Morrison & Foerster

Adam Kearney is an Of Counsel in our Corporate Group based in our Beijing office and specializes in China-related private equity and M&A transactions. He has represented many of the leading private equity houses and principal investment arms of U.S. investment banks active in the PRC market in a wide variety of transactions. Mr. Kearney’s clients include emerging growth companies, multinational corporations and Chinese state-owned enterprises in the healthcare, media, consumer, and financial services industries. He has also represented U.S. and European multinationals in their inbound investment and strategic acquisition activities in China.
Mr. Kearney graduated from Harvard College and Harvard Law School and speaks and reads Mandarin Chinese. Prior to joining Morrison & Foerster, Mr. Kearney was a partner at another U.S.-based international law firm, resident in that firm’s Beijing office. He has also served as an in-house consultant to a major U.S. specialty chemicals manufacturer in connection with its strategic acquisition activities in the PRC. He is admitted to practice in New York.

Alex Fowkes, JD - Head of R&D Business Development, Asia, Pfizer (China)

Alex Fowkes obtained undergraduate degrees in science and law in Australia before joining a private practice law firm in 1994. In 1998 Alex joined Pfizer’s operations in the United Kingdom to provide legal support to its European research and development activities. In 2003 Alex moved to the Pfizer Research and Development Division (PGRD) headquarters in New London, Connecticut to lead the global legal support for PGRD’s world-wide technology transfer activities. At the end of 2006 Alex was appointed to lead PGRD’s Strategic Alliance operations in Asia and relocated to Pfizer’s Research Office in Shanghai.

Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., USA

Dr. Jing-Shan (Jennifer) Hu is Director of Licensing & External Research (Mailand China, Hong Kong, & Taiwan) with Merck & Co, USA. She is responsible for identifying and developing new product and technology opportunities in Mainland China, Hong Kong, and Taiwan for Merck in the area of partnership, licensing-in, and acquisition. Prior to joining Merck, Jing-Shan spent three years at Roche Palo Alto as Research Leader, heading Functional Biology applying and developing new technologies towards assessment of drug targets and new compounds, following a role as Palo Alto Leader of Toxicogenomics. Prior to that, Jing-Shan worked at Affymetrix in various capacities, including establishing and managing programs with both pharmaceutical and academic partners to demonstrate the application of Affymetrix GeneChip technology in Toxicology/Pharmacogenomics studies. Jing-Shan started her career at Human Genome Sciences, Inc. as a scientist and later as Project Leader of its VEGF-2 Protein Therapeutics Program. Jing-Shan did her post-doctoral research at Harvard Medical School and Massachusetts General Hospital. She earned her Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center and her bachelor's degree from Peking University in Beijing. Jing-Shan has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications.

Julius Li, MBA - Co-Founder &CEO, AutekBio, Inc.

Julius Li is the Co-founder and CEO of AutekBio, Inc., the first therapeutic biologic CMO operating in China. In March, 2010, AutekBio signed a $100M investment agreement to build the first US / EU cGMP facility in China. Prior to setup AutekBio, He was the Co-Founder and Managing Director of GoldenGate Biopharma, a biotech company specialized in cross border biotech business consulting, which licensed a US marketed antibiotics to China. Mr. Li is a professional in the commercialization of biopharmaceutical products, encompassing research, development, marketing, finance and operation. He has taken technical and management positions in US and Chinese pharmaceutical companies, from startups to multinationals. At Guangzhou Baiyunshan Pharmaceutical Group, he led teams to launch two biochemical drugs. At Hoffmann La-Roche US division, he managed the technology transfer from development to manufacturing, and coordinated production. Mr. Li earned graduate degrees from Zhongshan University, Chinese Centers for Disease Control and Prevention (CDC) and the Ross Business School at the University of Michigan. He is also the current Deputy Director General of the National Engineering Center for Viral Biotechnology.

Chuck Ng - Managing Director, Suma Ventures

Chuck is Managing Director of Hambrecht Suma Capital and is involved in investments across the life science and other emerging technology sectors. His current portfolio includes a number of biotechnology companies in therapeutic discovery, CRO, CMO and other innovative technology companies with cross border strategy between US and China. Prior to Hambrecht Suma Capital, Chuck worked for eBay Inc. (NASDAQ: EBAY) and had responsibilities in int'l expansion and financial strategy of eBay's PayPal business unit. In this role, he led the expansion of PayPal's global footprints to Singapore (APAC HQ), Australia, China, Europe and the formation of PayPal Bank. As a result of his leadership, he had won the "PayPalian" Award, the highest award at PayPal as well as 4 "MVP" Awards. Prior to eBay, he worked for Chiron Corporation (now Novartis), the second largest biotech company by revenue after Genentech in San Francisco Bay Area, where he managed the global hedging program as well as the strategic investment at Chiron. Chuck is a graduate of the University of California, Berkeley and also studied at Tsinghua University in China. He is fluent in Mandarin, Cantonese and English, and is conversant in Japanese.

William Pan, PhD - Co-Founder & COO, R&D, Crown Bioscience (Taicang) Inc.

Dr. William (Wubin) Pan is a co-founder and the Chief Operation Officer of Crown Bioscience, Inc., a US company with major operation in China (Beijing & Shanghai) providing cost-effective quality CRO services for international biopharma companies, including major top 10 MNCs. He has over 20 years of extensive experiences in biosciences, especially biopharmaceutical R&D, with over 10-year experiences in Europe and North America. Dr. Pan was the VP for TsingHua YuanXing Biopharmaceutical Co., Ltd. (Shenzhen, China) when he came back to China as an entrepreneur in 2000. Between 2001 and 2006, he co-founded and served as Vice President and/or General Manager for a couple of biotech companies, where he played key roles for the development of several gene-based therapeutic biologics and was involved in the development and successful marketing of several biomedical products. Dr. Pan obtained his PhD in Biology in Sussex University (UK) and postdoctoral training at University of California at Berkeley.

Yi Shi, PhD - Managing Director, Lilly Asian Ventures

Dr. Yi Shi joined Lilly Asian Ventures in 2007 as a Managing Director based in Shanghai, China. Prior to the current assignment, he worked in various roles with increasing responsibility over six years at Eli Lilly and Company. His experience includes leading the development of a comprehensive investment strategy for China as well as negotiating multiple biotechnology and pre-clinical deals world-wide. Dr. Shi was also instrumental in the founding of InnoCentive, Inc., a Lilly Ventures portfolio company, where he managed scientific operations as well as its expansion into China. Before joining Lilly, Dr. Shi was the Chief Sales and Marketing Officer of NetBig.com, an internet start-up, where he successfully grew the company to become the number one education and technology portal in China. He began his career as a management consultant with Ernst & Young in the Life Science Practice Group and specialized in sales and marketing strategy. Dr. Shi received a PhD in Biochemistry and a Master of Business Administration degree, both from Duke University. He also earned a Bachelor of Science in Biology from the University of Science and Technology of China.

Catherine Sun, LLM - Managing Partner, Foley & Lardner LLP

Catherine Sun is the managing partner of the Shanghai Office of Foley & Lardner LLP and chair of the firm's Asia Practice. Ms. Sun is a member of the firm's Intellectual Property Litigation and International Practices is also a member of the firm's Life Sciences, Entertainment & Media and Automotive Industry Teams. She works with the firm's clients on IP strategy, counseling and litigation, cross border M&A related IP, international technology transfer, licensing and portfolio management.
For the past seventeen years, Ms. Sun has practiced in U.S., Hong Kong and Mainland China. Prior to joining Foley, she was with the Shanghai office of an international law firm, where she was head of the China IP Practice. Ms. Sun spent seven years practicing law in the United States as an attorney in the Washington, D.C. and northern Virginia offices of a major national law firm, as well as serving as an in-house attorney for a high-technology company. She returned first to Hong Kong and then to Shanghai to practice intellectual property law in 2002. In the early 1990s, Ms. Sun practiced intellectual property law in Beijing.
Ms. Sun received her LLM degree from the George Washington University Law School and earned her LLB degree from Peking University, with honors.

Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia

Dr. Jonathan Wang is a Senior Managing Director, at OrbiMed Asia. He is a general partner at OrbiMed’s Asia-focused VC fund. Previously, he was General Manager at Burrill Greater China Group and worked for WI Harper Group and Walden International, two pioneers in the Asia-related VC industry. At WI Harper, Dr. Wang was a Managing Director, overseeing the firm’s life sciences activities worldwide. There he co-founded and incubated Bridge Laboratories. Dr. Wang is a Board Director at ForteBio, Inc. He is also co-founder and former Chairman of The BayHelix Group, an organization of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific training under the supervision of Dr. Eric Kandel, a Nobel Laureate. Dr. Wang also earned an M.B.A. from Stanford University.

Xiaochuan Wang, PhD - Chairman and CEO, Sundia MediTech Co., Ltd.

Dr. Wang received her PhD degree from the University of Chicago in 1989, specialized in molecular structure design of new drugs. After her PhD training, she worked for 3 biotech companies in USA on R&D research and program management. She has 20 years experience in drug discovery and development for 14 different target, and successfully applied computer aided drug design, medicinal chemistry, compound library design and screening, and ADME analysis. She led teams of medicinal chemists, biologists, and pharmacologist to go through the whole process of drug discovery from 0 to clinical stages. Dr. Wang founded Sundia MediTech Company in Shanghai in 2004, and has led Sundia to grow into a leading Chinese CRO company, especially in new drug discovery CRO services. Sundia was selected by the top VC investors as one of the “Most Valuable Companies for Investment in China” in 2007 and 2008, and was honored in Deloitte High Tech High Growth Companies Top 50 in China, and Top 500 in Asia Pacific.

Tao Xiong, JD - Partner, Broad & Bright

Tao Xiong is a Partner at the Shanghai office of Broad & Bright. Tao's practice focuses primarily on representing multinational companies in cross-border mergers and acquisitions, joint ventures, private equity and venture capital investment, and general corporate matters. Tao has extensive experience counseling clients in a variety of industries, including biotechnology, pharmaceutical, information technology, and consumer products. Prior to joining Broad & Bright, Tao was an associate at O’Melveny & Myers LLP and K&L Gates LLP, both major international law firms, where her practice focused on mergers & acquisitions, private equity, securities and general corporate counseling. Tao began her legal career in 1998 as a lecturer-in-law with Renmin University of China School of Law, a top law school in China, where she taught courses on international business law. Tao received her JD and LLM, both from New York University School of Law. She also received her LLM and LLB, both from Renmin University of China School of Law. Tao is admitted to the National Bar of China, the State Bar of New York, and the State Bar of Pennsylvania.

Bai Xu, PhD - President & CEO, Suzhou Natong Nanobiotechnology Co., Ltd.

Graduated from University of Paris, The Molecular Materials Lab of National Center of Scientific Research, France, Dr. Xu’s professional activity focuses mainly on the development of micro-electro-mechanical systems, popularly known as MEMS. MEMS technology is the integration of sensors, actuators, together with electronics on single silicon chip or other substrate to enable a dramatic improvement in system performance. Dr. Xu was SEMI task force leader and co-leader for MEMS fluidic interface standards. He also served at the Editorial Board of “Nanomedicine: Nanotechnology, Biology and Medicine”. Before he devoted his full effort to Suzhou Natong, an intraepidermal drug repositioning company he co-founded, he was a founding faculty of world’s first college exclusively dedicated to nanotechnology research and education: College of Nanoscale Science and Technology (CNSE) at University at Albany. He served as Senator in CNSE Faculty Senate and committee members of CNSE Curriculum Committee, Qualifying Exam Committee, Faculty and Professional Staff Search Committee.

David Xu, PhD, MBA - Managing Partner, Mingly China Growth Fund

David Xu is the Managing Partner of Mingly China Growth Fund. David has over 10 years of investment banking experience in China. Previously, David worked at EBICC, Create Capital, China Fortune Securities and Goldman Sachs. He also worked as a research fellow at Columbia Medical Center for 7 years. David received his BS degree from University of Science & Technology of China, PhD in Microbiology from Columbia University, and MBA from MIT Sloan School of Management.

Stella Xu, PhD - Global Licensing Director, Roche Global Pharma Partnering

Dr. Stella Xu is the Global Licensing Director with Roche Global Pharma Partnering. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management with Asian partners. Prior to her current position, Stella had held multiple global positions in Roche Pharma Partnering and led more than 30 product-focused due diligence projects and alliances such as Toyama, Japan Tobacco, and Maxygen. Stella joined Roche from McKinsey & Company, a management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella was a research scientist with Isis Pharmaceuticals. Stella received her B.S. in Biophysics from Peking University; her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University.

Yanning Yi, MBA - Executive Director, The Balloch Group

Yanning Yi joined The Balloch Group in 2007 and is focused on the firm's investment banking practices in healthcare sector. Mr. Yi has worked with the healthcare team of CIBC World Markets originating IPO transactions in US. He has extensive experience on private equity deals for CRO, specialty pharma, drug discovery, and medical device companies, including KPCB’s most recent $15 million investment in Genscript. Prior to joining TBG, Mr. Yi worked at CIBC in Toronto where he focused on credit and investment portfolio risk management. Prior to that, Mr. Yi spent seven years with China's largest policy bank, the China Development Bank, where he completed over $3 billion debt transactions in power, mining, manufacturing, and infrastructure industries. Mr. Yi received his MBA from the University of Western Ontario, Canada and his BA in Economics from the China Institute of Finance and Banking.

Jingyang Zhu, PhD - Senior Vice President of Global Technical Operations, Chiral Quest

Dr. Zhu is Senior Vice President, Global Technical Operations for Chiral Quest. During his more than 20 years tenure in the Chemical and Pharmaceutical industry, he advanced his career successfully from a scientist to a Manager of Process Development Labs at Bristol-Myers Squibb, Syracuse, New York, then to a Director of Process Development at Nektar Therapeutics, Huntsville, Alabama. In 2007, he joined Chiral Quest as Vice President of Global R&D. During his last thirteen years at Bristol-Myers Squibb, Dr. Zhu has gained extensive experience in process R&D for all phases of pharmaceutical development. He demonstrated his ability of leading project teams in the development of chemical processes for preparing pharmaceutical intermediates and APIs. He is also instrumental in transferring process technologies from laboratories to production sites and in validating new processes and manufacturing sites. Dr. Zhu earned this PhD degree in the area of Organic and Organometallic Chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. His postdoctoral studies were conducted under the guidance of Professor James M. Takacs at University of Nebraska-Lincoln.

Tao Zhu, PhD - Co-Founder & Executive VP, Vaccine Development, Tianjin CanSino Biotechnology Inc.

Dr. Tao Zhu received his BS in biology from Tsinghua University in 1995 and his PhD in chemical engineering from University of Pittsburgh in 2002. He did his post doc training at Carnegie Mellon University. His PhD and Post doc research work focused on metabolic engineering of bacterial strain to produce various valuable secondary metabolites. Dr. Tao Zhu started his career in a small biotech company, Integrated Genomics Ltd at Chicago in 2004 and developed several metabolic engineering strategies using bioinformatics and modeling tool. He joined Sanofi Pasteur in 2006 as a senior scientist responsible for new vaccine process development. During his tenure, he made significant contribution in development of a few new vaccines. In 2009, he and three other partners co-founded CanSino Biotech Inc at Tianjin. He is now Executive VP of vaccine R&D.